Bayer's Aliqopa Approval Gives PI3K Class A Second Chance in Follicular Lymphoma
Executive Summary
Bayer's PI3 kinase inhibitor copanlisib now has accelerated approval in a common type of non-Hodgkin lymphoma, but the drug's competitive profile still awaits Phase III data.
You may also be interested in...
Verastem’s Copiktra Gets Early Approval To Challenge Zydelig, Venclexta In Third-Line CLL
Copiktra (duvelisib) becomes the first dual inhibitor of PI3K delta and gamma to hit the market, placing it in competition with Gilead’s Zydelig and AbbVie’s Venclexta.
Keeping Track: DMD, RMAT, HIV, BTDs, Tc-99m – FTW
The latest drug development news and highlights from our US FDA Performance Tracker.
Bayer's Weinand On Pricing, Payers And Pipelines
Bayer's pharma president and board member Dieter Weinand talks to Scrip about the importance of big picture thinking when weighing the value of innovative drugs to healthcare systems, the revolutionary potential of big data and how "transparency and open dialogue will further enhance the understanding of our business."